Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

By V. Pascual, F. Allantaz, Edsel Arce, M. Punaro, Jacques Banchereau. Journal of Experimental Medicine, 2005

956 citations recorded by the source corpus.

Systemic onset juvenile idiopathic arthritis (SoJIA) encompasses ∼10% of cases of arthritis that begin in childhood. The disease is unique in terms of clinical manifestations, severity of joint involvement, and lack of response to tumor necrosis factor blockade. Here, we show that serum from SoJIA patients induces the transcription of innate immunity genes, including interleukin (IL)-1 in healthy peripheral blood mononuclear cells (PBMCs). Upon activation, SoJIA PBMCs release large amounts of IL-1β. We administered recombinant IL-1 receptor antagonist to nine SoJIA patients who were refractory to other therapies. Complete remission was obtained in seven out of nine patients and a partial response was obtained in the other two patients. We conclude that IL-1 is a major mediator of the inflammatory cascade that underlies SoJIA and that this cytokine represents a target for therapy in this disease.

Subfields: Hematology, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/365e1bc26e65eaf8af71258c6f9c9eb2183a1160

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. T. Mak
2. T. Berger
3. David Mcilwain

In Molecular Biology

1. J. Sims
2. Dirk E. Smith
3. T. Mak
4. T. Berger
5. David Mcilwain

Citations in the corpus

• IL‐1, IL‐18, and IL‐33 families of cytokines (2008, background): “However, IL-1 blockade with anakinra has been highly beneficial in systemic-onset juvenile idiopathic arthritis and in adult onset Still’s disease (45, 46).”
• The IL-1 family: regulators of immunity (2010, background): “In the systemic onset form of JIA (SO-JIA), however, IL-1 has an important role, and treatment with anakinra is highly beneficial in many, but not all, case”
• Caspase functions in cell death and disease. (2013, background): “18 Cite this article as Cold Spring Harb Perspect Biol 2013;5:a008656 FMF patients (Roldan et al. 2008), HIDS patients (Cailliez et al. 2006), and sJIA patients (Pascual et al. 2005; Kelly and Ramanan 2008; Lequerre et al. 2008).”
• Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. (2012, neutral): “Other 1 (2) 4 (10) 19 (11) 7 (14) 7 (14)”
• Anti-inflammatory Agents: Present and Future (2010, neutral): “, 2005, 2009) Adult and Juvenile Still’s Disease (Fitzgerald et al., 2005; Pascual et al., 2005) Behçet’s Disease (Botsios et al.”